Drugs / HTMC0435
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05728619 | Feb 2023 → Aug 2024 | small cell lung carcinoma | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTMC0435 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05728619 ↗ |
| Route | Oral | “Oral administration.” NCT05728619 ↗ |